论文部分内容阅读
肝纤维化(HF)是继发于各种慢性肝损伤的一种组织修复过程,以肝星形细胞(HSC)激活和细胞外基质(ECM)过多产生为病理特征。HF是向肝硬化甚至原发性肝癌发展的一个中间环节。HF的早期治疗可以逆转或抑制其发展。因此,能否延缓、阻断或逆转HF的发展,具有重大意义。近年来抗HF药物的研究已进入细胞分子水平,少数已深入到细胞内信息控制水平。旨在通过抑制HSC的激活、诱导其凋亡和防止ECM沉积的干预性治疗在实验性阶段已取得疗效,但抗HF的临床有效性和安全性有待于进一步研究和论证。
Liver fibrosis (HF) is a tissue repair process secondary to various chronic liver injuries characterized by hepatic stellate cell (HSC) activation and extracellular matrix (ECM) overproduction. HF is an intermediate link to the development of cirrhosis and even primary liver cancer. Early treatment of HF can reverse or inhibit its development. Therefore, whether to delay, block or reverse the development of HF, of great significance. In recent years, research on anti-HF drugs has entered the molecular level of cells, a few have been deep into the level of intracellular information control. Interventional therapies aimed at inhibiting the activation of HSCs, inducing apoptosis and preventing the deposition of ECM have achieved therapeutic efficacy in the experimental phase, but the clinical efficacy and safety of anti-HF remain to be further studied and demonstrated.